Immune checkpoint inhibitors in the treatment of glioblastoma multiforme
DOI:
https://doi.org/10.18778/1730-2366.18.05Keywords:
glioblastoma multiforme, immunotherapy, immune checkpoint inhibitors, monoclonal antibodies, neurooncologyDownloads
Download data is not yet available.
References
Yasinjan, F., Xing, Y., Geng, H., Guo, R., Yang, L., Liu, Z., Wang, H. 2023. Immunotherapy: a promising approach for glioma treatment. Frontiers in Immunology, 14, 1255611.
Linares, C.A., Varghese, A., Ghose, A., Shide, S.D., Adeleke, S., Sanchez, E., Sheriff, M., Chargari, C., Rassy, E., Boussios, S. 2023. Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities. International Journal of Molecular Sciences, 24(17), 13215.
Downloads
Published
2024-09-18
Issue
Section
Articles
License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
Immune checkpoint inhibitors in the treatment of glioblastoma multiforme. (2024). Acta Universitatis Lodziensis. Folia Biologica Et Oecologica, 18, 13-13. https://doi.org/10.18778/1730-2366.18.05
